Tricida Annual Revenue, Competitors, Number of Employees and Funding

Claim your profile

Overview

Location:
Total Funding:$257M
Industry:Pharma
Founded:2013
Lead Investor(s):Hercules Capital
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Tricida's estimated annual revenue is currently $10.9M per year.
  • Tricida received $100.0M in venture funding in March 2018.
  • Tricida's estimated revenue per employee is $78,086
  • Tricida's total funding is $257M.

Employee Data

  • Tricida has 139 Employees.
  • Tricida grew their employee count by 72% last year.
  • Tricida currently has 19 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
$13.1M653%N/A
DURECT Corporat...
N/A120N/AN/A
Rancho BioScien...
$10.9M5423%N/A
ApotheCom
$45.2M225N/AN/A
Tlc Pharmacy
$8.6M435%N/A
Otsuka America
$11.5M5719%N/A
endpoint Clinic...
$59.7M29710%N/A
GCAM
$19.1M954%N/A
VistaGen Therap...
N/A16N/AN/A
Pliant Therapeu...
$10.9M5417%N/A
Missing a competitor? Contribute!?
Submit

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its late-stage investigational product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. We recently completed a successful Initial Public Offering and our stock is listed on the Nasdaq Global Select Market under the symbol TCDA. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101. Tricida's shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients. Highly Competitive Compensation and Benefits

keywords:Analytics,Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

139

Number of Employees

$10.9M

Revenue (est)

19

Current Jobs

72%

Employee Growth %

$257M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Geoffrey ParkerChief Financial Officer And Senior Vice President
Judd KatzVice President Legal & Compliance
Matt FordVice President Human Resources
Adam FrancisSr Director, Forecasting & Analytics
Angela LawProject Manager, Legal Affairs Operations
Yundi ChiuDirector, Internal Audit - Sox Compliance
Paul WilliamsCorporate Account Director
Brian HuestonSr Director, Market Access
Gerrit KlaernerCEO/PresidentEmail Available
David LaoPrincipal Research Associate

Tricida News

09/03/2019 - Tricida Announces Submission of New Drug Application for ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. NDA Submitted under the FDA's Accelerated Approval Program. Tricida, Inc. (TCDA), a ...

09/04/2019 - Tricida (TCDA) Announces Submission of New Drug ...

Tricida (TCDA) Announces Submission of New Drug Application for Veverimer for Treatment of Metabolic Acidosis in Patients with CKD.

09/03/2019 - Claire Lockey Sells 10000 Shares of Tricida Inc (NASDAQ ...

Tricida Inc (NASDAQ:TCDA) VP Claire Lockey sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd.

Tricida Funding

DateAmountRoundLead InvestorsReference
2014-02-03$4.5MUndisclosedArticle
2015-03-05$30.0MBOrbiMedArticle
2016-07-26$55.0MCLongitude CapitalArticle
2017-11-09$57.5MDWellington Management Company LLPArticle
2018-03-05$100.0MUndisclosedHercules CapitalArticle

Tricida Executive Hires

DateNameTitleReference
2016-01-13Claire LockeyChief Development Officer/SVPArticle
2017-02-16Wilhelm StahlSVP/Chief Technology OfficerArticle
2017-04-12Geoffrey ParkerSVP/CFOArticle
2018-01-09Jeroen van BeekSVP & Chief Commercial OfficerArticle
2018-08-02Dawn ParsellSVP Clinical DevelopmentArticle
2019-01-18Susannah CantrellSVP/Chief Commercial OfficerArticle